Patent · US Active

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

US11541103B2 · kind B2 · utility

4Cited by

58References

34Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Khaled M. K. Z. Ali · Thousand Oaks, US
Neeraj Jagdish Agrawal · Thousand Oaks, US
Gunasekaran Kannan · Daly City, US
Ian Foltz · Burnaby, CA
Zhulun Wang · Palo Alto, US
Darren L. Bates · Oak Park, US
Marissa MOCK · Newbury Park, US
Shunsuke Takenaka · Thousand Oaks, US

Key dates

Filing date	Aug 3, 2018
Grant date	Jan 3, 2023
Priority date	—
Expiry date	Dec 3, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/10041
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.